UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease
The Hospital for Sick Children
4,100 participants
Aug 24, 2018
OBSERVATIONAL
Conditions
Summary
Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.
Eligibility
Inclusion Criteria19
- Cohort 1: - Biologic Basis of JIA
- ≤18 years*
- Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment
- Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis
- Cohort 2 - Start Biologics
- JIA diagnosis as per ILAR criteria (all subtypes)
- ≤18 years*
- Active arthritis
- For sJIA, active disease not necessarily with arthritis.
- Time of start, restart or switch biologic therapy: e.g. failure, insufficient/partial response or intolerance
- Cohort 3 - Stop Biologics
- JIA diagnosis as per ILAR criteria (all subtypes)
- ≤18 years*
- Inactive disease
- Discontinuing/tapering biologics for inactive disease
- Cohort 4: Extreme Phenotypes
- Unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations
- High suspicion of genetic contribution
- Severely affected patients with difficult to control disease (ie failure of multiple biologics)
Exclusion Criteria10
- Cohort 1 :
- Arthritis explained by another diagnosis
- Joint injections as previous treatment less than 4 weeks prior to enrollment
- Cohort 2:
- Arthritis explained by any other cause
- Start on biologics as an indication for uveitis only
- Cohort 3:
- \- Tapering scheme > 12 months to complete biologics stop
- Cohort 4:
- \- Arthritis explained by another diagnosis
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06560606